NCT07323654

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 264 (estimated)
• Sponsor: Kymera Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Conditions

• Eosinophilic Asthma

Interventions

Type	Name	Description
DRUG	KT-621	Oral drug
OTHER	Placebo	Oral placebo matched to KT-621

Timeline

• Start date: 2026-01-28
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2026-01-07
• Last updated: 2026-03-18

Locations

9 sites across 1 country: United States

Regulatory

• FDA-regulated drug study